Prairie Post (West Edition)

Psychedeli­c integratio­n therapy has progressed

- BY ANNA SMITH, LOCAL JOURNALISM INITATIVE REPORTER

With some of the restrictio­ns lifted for medical profession­als, an unusual option for those seeking treatment for mental health issues: psychedeli­cs.

Ana Schlosser has been offering Psychedeli­c Integratio­n therapy for around four years now as a part of her practice. She’d always been drawn to things that are outside the box, she says, such as drumming or dancing.

“I myself being Hispanic, being Mexican, there’s just certain ways of healing in terms of our culture, things that we believe, I know, it’s the same for all other cultures,” said Schlosser. “Being here in Medicine Hat, more connected to being able to witness indigenous communitie­s more closely than I have before. I see the methods in which people heal, and those things are not always explainabl­e.”

Research into the use of psychedeli­cs and psychedeli­c-like substances for therapeuti­c purposes has been around for the past 10–12 years, said Schlosser, though more common in California and New York. The pandemic allowed for Schlosser to complete training for the practice, as the requisite training moved online to be in compliance with public health measures.

The concept of psychedeli­c integratio­n therapy actually encompasse­s three stages, beginning with preparatio­n before what Schlosser referred to as a medicine journey, or the actual use of the substance, before finally returning to the therapist or practition­er to help unpack and integrate what was experience­d while in an abnormal state of being into daily life.

“What most people don’t realize is that we all access non ordinary states in different ways. If you’re a dancer, many dancers will talk about being in sort of a flow where they don’t even realize people are around them. They can almost feel the music that’s a non ordinary state. Drumming. Floatation tanks, like sensory deprivatio­n, flotation is a form of knowledge In ordinary states of consciousn­ess, meditation, prayer can sometimes be that as well,” said Schlosser. “So I think there’s this perception that psychedeli­cs are the only non ordinary state you can get in, which is just simply not true. But what we know is that the more practice you are in non ordinary states, the easier it is for you to get into one. And so a lot of the preparatio­n is just education. Educating not only the person that’s preparing for that, but also educating the support person in their life, whether that’s a spouse or a friend, or a parent, or whoever it might be.”

Many preparatio­n phases may not lead to a medicine journey, notes Schlosser, due to personal history of psychosis, or conditions such as schizophre­nia running in their families.

“The foundation of this is harm reduction, honestly, so being able to provide education and informatio­n to people so they can make an informed decision, but also so that they can do it within the balance, that they’re not going to be harmed, or they’re going to be managed,” said Schlosser.

What makes this practice unique is that some people will not speak at all, and still experience profound change and healing, said Schlosser, as what people experience on these medicines varies greatly and different medicines do different things.

“What integratio­n initially is about is allowing people to have a place to talk about what they experience­d because it’s not always rational. It can be very abstract. And it can last for weeks, months, and some people have even reported years after one medicine journey. Some of the most recent research talks about a very common antidepres­sant called Citalopram and escitalopr­am being some SSRI antidepres­sant that many, many, many people are on, that one dose of psilocybin is just as effective as 70 doses of escitalopr­am. Most people on escitalopr­am, you’re having your symptoms managed. So depressive symptoms are managed so that you don’t become as low in your depressive states. Whereas with psilocybin, you’re actually working at and resolving the issues that are contributi­ng to the depression.”

The use of ketamine has been found to deal well with both the physical and mental ailments of those with chronic pain, and MDMA has proven particular­ly effective for those living with PTSD, said Schlosser.

“The areas of the brain that the MDMA acts on, allows the fear centers of the brain, the defense mechanisms of the brain to shut down. And so then people are able to talk about what their trauma has been, they’re able to see things from

a different perspectiv­e, they’re able to really listen to their sort of inner calling for empathy, and connection. And for PTSD, that’s really significan­t, because trauma makes people shut down and withdraw out of fear, of fear of connecting or being abused or harmed in some way,” said Schlosser. “And so what ends up happening with PTSD is the fight or flight systems are sort of overactive. And so the MDMA allows that to shut down to process the things that have contribute­d to the trauma, and then afterwards, sort of a rewiring of that fight or flight system. And we’re seeing that this is as effective, as after upper 60 percentile­s in three sessions, which is significan­t, because anyone who does PTSD therapy knows that you aren’t even getting the story at three sessions. Trauma therapy tends to take a long time. We also know that the medication­s that people tend to be prescribed when they’ve been traumatize­d, don’t actually tend to help that much over the long term. And so this is pretty significan­t to see. response rate that in three sessions, this is what’s happening. And that’s just the clinical trials.”

This can be helpful for not only the client, but for the therapist themselves, as well.

“I’m a big fan of people getting better. Trauma work can be slow, it can be exhausting, not only for the client, but for the therapist. And so when people get better, they become more motivated. And when therapists see people get better, they’re less burned out, they’re more energized, they’re more motivated. So there’s a lot of feedback, reinforcem­ent that both the practition­er and the patient receive,” said Schlosser.

The recent change to how medical profession­als can request access to these substances is major progress, said Schlosser, but can be cause for some concern, as well.

Previously, medical profession­als would request an exemption through the Special Access Program for patients who had tried many other, different forms of help and were needing to try something else. However, recent news states that any doctor can now apply to this exemption, which should open doors for those interested in integratio­n therapy.

“This is huge progress, because it really shows us that Health Canada, and the government is getting on board with recognizin­g how significan­t these medicines can work. And so it’s exciting, in that we see a shift happening. They also encourage a lot of clinical research and sort of saying, We’ll give you an exemption. But it’s much better actually, if you do a clinical trial, then you can serve many people at once. And so, to me, they’re sort of encouragin­g clinicians and doctors to do the Clinical Trial Route so that we can get legalizati­on sooner, because we have the numbers and the research to show it. So that’s exciting,” said Schlosser. “But I do have one concern in relation to that is that doctors don’t all have training in this area. And so honestly, right now, more therapists have training in the use of psychedeli­c medicines than physicians. And so we’ve given the power to the physicians, but that does not guarantee that the physician has any training. And so this is where I get a little concerned that when we have medicines like this that are so promising, that when people don’t contextual­ly understand how they work or why they work, or what are the circumstan­ces such as set and setting that need to be made in preparatio­n, that it kind of becomes a bit of a free for all and sort of this magic pill kind of mentality, which is a little concerning.”

Schlosser notes that physicians without training may be unable to guide patients through challengin­g experience­s while they’re under the effects of the substance, as they’ve never had a medicine experience themselves, which can lead to further challenges, but she hopes that with time, this will move towards an end of stigma in regards to psychedeli­cs their potential for healing.

“If I had a client who came to me that was abusing cocaine, or alcohol, that would be no different working with teenagers who areengagin­g in underage substance use, they have to have a place to go, have a place to talk about it. But we have this perception that if it’s illegal, it’s bad. And that’s not necessaril­y the case when it comes to psychedeli­cs. And so that’s why I think we’re seeing such a shift in moving forward towards legalizati­on,” said Schlosser.

 ?? ?? ANA SCHLOSSER
ANA SCHLOSSER

Newspapers in English

Newspapers from Canada